Search

Your search keyword '"PROSTATE-SPECIFIC ANTIGEN"' showing total 705 results

Search Constraints

Start Over You searched for: Descriptor "PROSTATE-SPECIFIC ANTIGEN" Remove constraint Descriptor: "PROSTATE-SPECIFIC ANTIGEN" Database OAIster Remove constraint Database: OAIster
705 results on '"PROSTATE-SPECIFIC ANTIGEN"'

Search Results

1. Impact of PSMA PET on Prostate Cancer Management

2. Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

3. Application of next-generation imaging in biochemically recurrent prostate cancer.

4. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.

5. Transcriptome-wide association analysis identifies candidate susceptibility genes for prostate-specific antigen levels in men without prostate cancer.

6. Performance of 4Kscore as a reflex test to prostate-specific antigen in the GÖTEBORG-2 prostate cancer screening trial

7. Performance of 4Kscore as a reflex test to prostate-specific antigen in the GÖTEBORG-2 prostate cancer screening trial

8. Performance of 4Kscore as a reflex test to prostate-specific antigen in the GÖTEBORG-2 prostate cancer screening trial

9. Co-designing an online treatment decision aid for men with low-risk prostate cancer: Navigate

10. Performance of 4Kscore as a reflex test to prostate-specific antigen in the GÖTEBORG-2 prostate cancer screening trial

11. Comparative Study of Eclipse and RayStation Multi-Criteria Optimization-Based Prostate Radiotherapy Treatment Planning Quality

12. Allergy to human seminal fluid: Cross-reactivity with dog dander

13. A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.

14. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer.

15. The influence of the cancer label on perceptions and management decisions for low-grade prostate cancer.

16. Risk of progression following a negative biopsy in prostate cancer active surveillance.

17. MRI as a screening tool for prostate cancer: current evidence and future challenges.

18. Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death.

19. Early biochemical outcomes following PSMA guided approach for bIoCHEmical relapse after prostatectomy-PSICHE trial (NCT05022914): preliminary results.

20. Genetically adjusted PSA levels for prostate cancer screening.

21. Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT).

22. Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.

23. Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.

24. The natural history of a delayed detectable PSA after radical prostatectomy.

25. Use of serum Prostate Specific Antigen doubling time kinetics to predict salvage surgery success following radical prostatectomy

26. Outcomes of Second-Line Therapies in Patients With Metastatic de Novo and Treatment-Emergent Neuroendocrine Prostate Cancer: A Multi-Institutional Study.

27. Use of the Decipher genomic classifier among men with prostate cancer in the United States.

28. Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program.

29. Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel.

30. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

31. One Year Radiographic Response Following Prostrate SBRT: An Exploratory Analysis of a Phase III Randomized Trial

32. ANALYSIS OF THE DYNAMICS OF PROSTATE CANCER DIAGNOSIS IN THE REGIONAL HOSPITAL DURING THE PERIOD 2018 – 2022

33. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis

34. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy

35. Accommodating heterogeneous missing data patterns for prostate cancer risk prediction.

36. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists

37. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists

38. Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer : A qualitative study

39. Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer : A qualitative study

40. Prussian Blue Nanozymes with Enhanced Catalytic Activity: Size Tuning and Application in ELISA-like Immunoassay

41. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists

42. Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer : A qualitative study

43. Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer : A qualitative study

44. Accommodating heterogeneous missing data patterns for prostate cancer risk prediction.

45. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.

46. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.

47. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists

48. Identifying the Risks and Drivers of Aggression in Prostate Cancer

49. Capacitive label-free ultrasensitive detection of PSA on a covalently attached monoclonal anti-PSA antibody gold surface

50. Signs and symptoms in relation to progression, experiences of an uncertain illness situation in men with metastatic castration-resistant prostate cancer : A qualitative study

Catalog

Books, media, physical & digital resources